Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grape extract may shield hearts of breast cancer patients during chemo

NCT ID NCT07419711

Disease control Sponsor: Nazarbayev University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study tests whether a daily grape polyphenol concentrate can reduce heart damage in women receiving certain chemotherapies for breast cancer. 120 women at high risk of heart problems will take either the supplement or a placebo for three months. Researchers will measure heart function and blood markers of injury at several time points.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
grape polyphenol concentrate
What this could lead to
If it works, this could point toward a simple dietary supplement to reduce heart damage from certain breast cancer chemotherapies.
What could go wrong
This is a small pilot study, not yet recruiting. The supplement may not provide significant heart protection, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 30 to 75 years. * Histologically confirmed breast cancer. * Planned treatment with anthracycline- and/or trastuzumab-based chemotherapy. * High or very high risk of chemotherapy-induced cardiotoxicity (≥20%), based on clinical assessment. * Eastern Cooperative Oncology Group (ECOG) performance status 0-3. * Ability to take oral study products. * Willingness to comply with study procedures and follow-up visits. * Written informed consent provided prior to any study procedures. Exclusion Criteria: * ECOG performance status of 4. * Pre-existing severe cardiovascular disease that would interfere with study participation. * Permanent atrial fibrillation or other clinically significant arrhythmias. * Severe hepatic or renal impairment. * Active central nervous system tumors or metastases. * Uncontrolled arterial hypertension. * Acute gastrointestinal diseases that may impair absorption. * Known allergy or intolerance to grape products or study components. * Participation in another interventional clinical trial that may interfere with the outcomes of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy-induced cardiotoxicity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.